10 publications in total
JAB-30355: A highly potent, orally bioavailable p53 Y220C reactivator
2024 AACR Annual Meeting
Apr, 2024
JAB-26766: a small-molecule, orally bioavailable PARP7 inhibitor with high potency and selectivity
2024 AACR Annual Meeting
Apr, 2024
Preliminary Activity and Safety Results of KRAS G12C Inhibitor Glecirasib (JAB-21822) in Patients with Pancreatic Cancer and Other Solid Tumors
2024 ASCO GI
Jan, 2024
Glecirasib (KRAS G12C Inhibitor) in Combination with JAB-3312 (SHP2 Inhibitor) in Patients with KRAS p.G12C Mutated Solid Tumors
2023 ESMO
Oct, 2023
Glecirasib (JAB-21822, KRAS G12C inhibitor) Monotherapy and in Combination with Cetuximab in Patients with Advanced Colorectal Cancer
2023 JCA-AACR Precision Cancer Medicine International Conference
Jun, 2023
JAB-X1800: a potent immunostimulatory antibody-drug conjugate (iADC) targeting CD73
2023 AACR Annual Meeting
Apr, 2023
JAB-2485: a potent, highly selective small-molecule Aurora kinase A inhibitor that targets cell division
2023 AACR Annual Meeting
Apr, 2023
Preclinical investigation of orally bioavailable, potent KRASmulti inhibitor JAB-23425
2023 AACR Annual Meeting
Apr, 2023
Results of KRAS G12C inhibitor Glecirasib as a single agent or in combination with SHP2 inhibitor JAB-3312
2022 European Society of Medical Oncology ASIA (ESMO ASIA)
Dec, 2022
A Phase I/II study of first-in-human trial of Glecirasib (KRAS G12C inhibitor) in advanced solid tumors
2022 annual meeting of American Society of Clinical Oncology (ASCO)
Jun, 2022

Platform & Pipeline

Partnership